Trade Legend Biotech Corporation - LEGN CFD
What is Legend Biotech Corporation (LEGN)?
Legend Biotech Corporation is a biotechnology company engaged in the research, development, and commercialization of innovative cell therapies for the treatment of cancer and other serious diseases. The company focuses on developing chimeric antigen receptor T-cell (CAR-T) therapies, which involve engineering patients' immune cells to target and destroy malignant cells. Legend Biotech collaborates with various partners in the pharmaceutical and biotechnology sectors to advance its pipeline of therapeutic candidates. Its research efforts aim to address unmet medical needs by leveraging cutting-edge cellular and genetic technologies. The company operates with a commitment to advancing scientific knowledge and improving patient outcomes through novel treatment modalities. Legend Biotech's activities encompass clinical development, regulatory engagement, and manufacturing of cell therapy products. It maintains a global perspective in its operations, seeking to bring innovative therapies to patients worldwide.
Legend Biotech Corporation Stock Price Today: Live Overview
The price today is shaped by trading activity, as Centessa Pharmaceuticals Limited trades at $19.06. It has fluctuated within a range from $18.59 to $19.25, marking a daily percentage change of -0.6835%.
FAQ: Legend Biotech Corporation (LEGN)
What is the current price of LEGN stock?
The stock price is currently $19.06.
Does LEGN pay dividends?
Dividends are not paid by the company.
Does LEGN have a formal corporate presence or regional headquarters in the UAE?
Legend Biotech Corporation operates through partners and distributors in the UAE without a direct office or subsidiary.
What is LEGN best known for?
Legend Biotech Corporation is most famous for its development of cell therapy products.
What assets are typically shown together with LEGN?
Commonly shown alongside LEGN: Xtrackers MSCI World Value UCITS ETF, Bentley Systems, Incorporated, Vanguard FTSE Developed Europe UCITS ETF
Latest shares articles



